Tandem Diabetes Care Inc. (NASDAQ:TNDM)’s share price dropped 1.2% during trading on Thursday . The stock traded as low as $6.33 and last traded at $6.45, with a volume of 179,015 shares traded. The stock had previously closed at $6.53.

TNDM has been the topic of several research analyst reports. Piper Jaffray Cos. reissued a “buy” rating and issued a $12.00 target price on shares of Tandem Diabetes Care in a report on Thursday, April 21st. Robert W. Baird restated a “buy” rating on shares of Tandem Diabetes Care in a research report on Monday, May 2nd. Zacks Investment Research upgraded shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $9.25 price target on the stock in a research report on Wednesday, May 4th. Sterne Agee CRT restated a “neutral” rating on shares of Tandem Diabetes Care in a research report on Monday, May 16th. Finally, Wedbush restated an “outperform” rating and issued a $20.00 price target on shares of Tandem Diabetes Care in a research report on Wednesday, June 15th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company’s stock. Tandem Diabetes Care presently has an average rating of “Hold” and an average price target of $14.21.

The firm’s 50-day moving average price is $7.23 and its 200-day moving average price is $7.99. The stock’s market cap is $199.29 million.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, July 28th. The medical device company reported ($0.60) EPS for the quarter, topping analysts’ consensus estimates of ($0.65) by $0.05. The firm had revenue of $23 million for the quarter, compared to analyst estimates of $23.08 million. Tandem Diabetes Care’s revenue for the quarter was up 46.5% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.65) EPS. On average, equities analysts expect that Tandem Diabetes Care Inc. will post ($2.14) EPS for the current fiscal year.

In other news, EVP John F. Sheridan sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $6.52, for a total transaction of $97,800.00. Following the sale, the executive vice president now owns 22,763 shares of the company’s stock, valued at approximately $148,414.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).